Barclays’s Transphorm, Inc. Common Stock TGAN Stock Holding History

Barclays’s Portfolio TGAN Stock Details TGAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-20,957	Closed	-$103K	–	5406
2024 Q1	$103K	Sell	20,957 -19,562	-48%	-$92.8K	﹤0.01%	4425
2023 Q4	$148K	Buy	40,519 +35,006	+635%	+$95.9K	﹤0.01%	4532
2023 Q3	$12.2K	Buy	5,513 +96	+2%	+$268	﹤0.01%	4272
2023 Q2	$18.4K	Sell	5,417 -6,226	-53%	-$22.5K	﹤0.01%	4150
2023 Q1	$46.5K	Buy	11,643 +5,534	+91%	+$24.4K	﹤0.01%	4470
2022 Q4	$33.2K	Buy	6,109 +5,144	+533%	+$30.3K	﹤0.01%	4685
2022 Q3	$5K	Sell	965 -111	-10%	-$547	﹤0.01%	4515
2022 Q2	$4K	Buy	+1,076	New	+$6.87K	﹤0.01%	4825

Barclays's TGAN Position: Q2 2024 in Review

Barclays sold out of Transphorm, Inc. Common Stock (TGAN) in Q2 2024, closing a stake of 20,957 shares — an estimated $103K sold.

Barclays first reported a position in TGAN in Q2 2022 and held it in 8 quarters. The position peaked at $148K in Q4 2023. 0 funds tracked by Wall St. Rank hold TGAN as of Q2 2024.

Barclays reported no remaining Transphorm, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Barclays sold 20,957 Transphorm, Inc. Common Stock shares in Q2 2024, an estimated $103K.
Barclays first reported a position in Transphorm, Inc. Common Stock in Q2 2022 and held it in 8 quarters.
Barclays's Transphorm, Inc. Common Stock position peaked at $148K in Q4 2023.
0 funds tracked by Wall St. Rank held Transphorm, Inc. Common Stock as of Q2 2024.

Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.